New symptomatic therapies for Huntington disease

Area of Science:

• Neurodegenerative Diseases
• Genetics
• Pharmacology

Background:

• Huntington disease (HD) is an inherited neurodegenerative disorder caused by a CAG repeat expansion.
• Mutant huntingtin protein leads to neuronal damage, with motor symptoms like chorea often following cognitive and behavioral changes.
• Current FDA-approved treatments like tetrabenazine primarily address chorea, leaving significant unmet needs for other symptoms.

Purpose of the Study:

• To review the current landscape of symptomatic therapies for Huntington disease.
• To highlight the unmet needs in treating non-motor symptoms, including cognitive and behavioral deficits.
• To discuss emerging pharmacologic and non-pharmacologic interventions under investigation for HD.

Main Methods:

• Literature review of approved and investigational therapies for Huntington disease.
• Analysis of current drug development targets, including phosphodiesterase 10 inhibition and dopamine modulation.
• Examination of non-pharmacologic interventions and their potential role in managing HD symptoms.

Main Results:

• Tetrabenazine and deutetrabebenazine are effective for chorea but do not address other HD symptoms.
• Several agents are under investigation for motor and non-motor symptoms, including PBT2 (metal chaperone) and latrepirdine (mitochondrial stabilizer) for cognitive benefits.
• There is a significant lack of evidence for effective treatments for behavioral and psychiatric symptoms in HD, and physical therapy is being explored.

Conclusions:

• While chorea management has options, substantial needs remain for therapies addressing gait, cognition, and behavior in Huntington disease.
• Future HD symptomatic therapies will likely focus on novel molecular targets and a broader range of interventions, including non-pharmacologic approaches.
• Continued research into the molecular mechanisms of HD is crucial for developing more comprehensive and effective symptomatic treatments.